Coya Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
A Schedule 13G filing reveals Orin Hirschman and AIGH Capital Management LLC's beneficial ownership of Coya Therapeutics, Inc. common stock.
NASDAQ
Dr. Reddy's Laboratories, Inc. and its parent entities have disclosed a 9.7% passive beneficial ownership stake in Coya Therapeutics, Inc.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, disclosing its beneficial ownership in Coya Therapeutics Inc. has fallen to 4.29% following an internal realignment.
NASDAQ
AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing beneficial ownership in Coya Therapeutics, Inc. common stock.
NASDAQ
Affiliates of Greenlight Capital, including David Einhorn, have disclosed a 9.9% beneficial ownership stake in Coya Therapeutics, Inc. as of December 31, 2024, according to a recent Schedule 13G/A filing.
NASDAQ
SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Disclose Significant Passive Stake in Coya Therapeutics
AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing their combined passive beneficial ownership of 8% of Coya Therapeutics, Inc.'s common stock as of December 31, 2024.